X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (104) 104
index medicus (102) 102
hematology (65) 65
male (65) 65
middle aged (63) 63
adult (62) 62
female (56) 56
aged (47) 47
chemistry (43) 43
metallurgy (43) 43
oncology (40) 40
treatment outcome (38) 38
abridged index medicus (36) 36
microbiology (34) 34
minimal residual disease (34) 34
antineoplastic combined chemotherapy protocols - therapeutic use (33) 33
beer (33) 33
biochemistry (33) 33
compositions or test papers therefor (33) 33
condition-responsive control in microbiological orenzymological processes (33) 33
enzymology (33) 33
measuring or testing processes involving enzymes, nucleicacids or microorganisms (33) 33
mutation or genetic engineering (33) 33
processes of preparing such compositions (33) 33
spirits (33) 33
vinegar (33) 33
wine (33) 33
prognosis (31) 31
rituximab (26) 26
survival (25) 25
adolescent (24) 24
therapy (23) 23
aged, 80 and over (22) 22
organic chemistry (22) 22
disease-free survival (21) 21
prospective studies (20) 20
leukemia, lymphocytic, chronic, b-cell - drug therapy (18) 18
fludarabine (17) 17
remission induction (17) 17
chemotherapy (15) 15
transplantation (15) 15
chronic lymphocytic-leukemia (14) 14
cyclophosphamide (14) 14
follow-up studies (14) 14
leukemia, lymphocytic, chronic, b-cell - mortality (14) 14
leukemia, lymphocytic, chronic, b-cell - therapy (14) 14
neoplasm, residual - diagnosis (14) 14
survival analysis (14) 14
leukemia, lymphocytic, chronic, b-cell - genetics (13) 13
polymerase-chain-reaction (13) 13
acute lymphoblastic-leukemia (12) 12
antineoplastic combined chemotherapy protocols - adverse effects (12) 12
combined modality therapy (12) 12
genomic aberrations (12) 12
polymerase chain reaction (12) 12
stem-cell transplantation (12) 12
transplantation, autologous (12) 12
bone-marrow-transplantation (11) 11
cancer (11) 11
chronic lymphocytic leukemia (11) 11
leukemia, lymphocytic, chronic, b-cell - pathology (11) 11
mutation (11) 11
time factors (11) 11
acyclic or carbocyclic compounds (10) 10
antineoplastic agents - therapeutic use (10) 10
chemical or physical processes, e.g. catalysis or colloidchemistry (10) 10
cyclophosphamide - administration & dosage (10) 10
flow cytometry (10) 10
human necessities (10) 10
hygiene (10) 10
immunoglobulin heavy chains - genetics (10) 10
investigating or analysing materials by determining theirchemical or physical properties (10) 10
leukemia (10) 10
measuring (10) 10
medical or veterinary science (10) 10
peptides (10) 10
performing operations (10) 10
physical or chemical processes or apparatus in general (10) 10
physics (10) 10
preparations for medical, dental, or toilet purposes (10) 10
recurrence (10) 10
risk factors (10) 10
specific therapeutic activity of chemical compounds ormedicinal preparations (10) 10
testing (10) 10
their relevant apparatus (10) 10
translocation, genetic (10) 10
transporting (10) 10
young adult (10) 10
clinical trials (9) 9
clinical-significance (9) 9
cll (9) 9
neoplasm, residual (9) 9
progression-free survival (9) 9
antineoplastic combined chemotherapy protocols - administration & dosage (8) 8
base sequence (8) 8
follow-up (8) 8
hematopoietic stem cell transplantation - methods (8) 8
leukemia, lymphocytic, chronic, b-cell - diagnosis (8) 8
lymphoma (8) 8
mantle cell lymphoma (8) 8
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (183) 183
German (23) 23
French (17) 17
Spanish (3) 3
Chinese (2) 2
Danish (2) 2
Korean (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 7, pp. 928 - 942
Journal Article
Lancet, The, ISSN 0140-6736, 2012, Volume 379, Issue 9828, pp. 1791 - 1799
Summary Background The intensity of chemotherapy and need for additional radiotherapy in patients with advanced stage Hodgkin's lymphoma has been unclear. We... 
Internal Medicine | SURVIVAL | ABVD | MEDICINE, GENERAL & INTERNAL | COMBINATIONS | POSITRON-EMISSION-TOMOGRAPHY | DISEASE | PROGNOSTIC SCORE | RISK | STANFORD-V | PROGRESSION | MOPP/ABV HYBRID | Doxorubicin - therapeutic use | Prospective Studies | Hodgkin Disease - pathology | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Positron-Emission Tomography | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Hodgkin Disease - radiotherapy | Bleomycin - therapeutic use | Treatment Failure | Hodgkin Disease - drug therapy | Adult | Female | Radiotherapy Dosage | Etoposide - adverse effects | Prednisone - adverse effects | Proportional Hazards Models | Etoposide - therapeutic use | Treatment Outcome | Bleomycin - adverse effects | Procarbazine - adverse effects | Procarbazine - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Survival Analysis | Vincristine - therapeutic use | Vincristine - adverse effects | Neoplasm Staging | Doxorubicin - adverse effects | Prednisone - therapeutic use | Chemotherapy | Usage | Care and treatment | PET imaging | Diagnosis | Hodgkin's disease | Cancer | Medical imaging | Meetings | Patient safety | Oncology | Lymphomas | Histology | Radiation therapy | Ovarian cancer | Index Medicus | Abridged Index Medicus
Journal Article
Lancet, The, ISSN 0140-6736, 2016, Volume 388, Issue 10044, pp. 565 - 575
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 09/2011, Volume 29, Issue 26, pp. 3559 - 3566
Journal Article
The Lancet, ISSN 0140-6736, 05/2019, Volume 393, Issue 10184, pp. 1948 - 1957
Docetaxel-based chemotherapy is effective in metastatic gastric and gastro-oesophageal junction adenocarcinoma. This study reports on the safety and efficacy... 
SURGERY | REGRESSION | MEDICINE, GENERAL & INTERNAL | MULTICENTER | RESECTION | CHEMORADIOTHERAPY | OPEN-LABEL | ESOPHAGEAL | CANCER | STOMACH | Capecitabine - administration & dosage | Leucovorin - administration & dosage | Adenocarcinoma - pathology | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Male | Oxaliplatin - therapeutic use | Stomach Neoplasms - pathology | Cisplatin - administration & dosage | Fluorouracil - therapeutic use | Docetaxel - administration & dosage | Fluorouracil - administration & dosage | Aged, 80 and over | Adult | Female | Leucovorin - therapeutic use | Oxaliplatin - administration & dosage | Administration, Oral | Esophagogastric Junction - pathology | Treatment Outcome | Capecitabine - therapeutic use | Stomach Neoplasms - drug therapy | Adenocarcinoma - drug therapy | Disease-Free Survival | Digestive System Surgical Procedures | Cisplatin - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Docetaxel - therapeutic use | Aged | Neoplasm Staging | Adenocarcinoma | Anthracyclines | Chemotherapy | Leucovorin | Product development | Esophageal cancer | Cancer | Intravenous administration | Control methods | Toxicity | Clinical trials | Oncology | Metastasis | Cancer therapies | Stomach cancer | Metastases | Confidence intervals | Infusion | Oxaliplatin | Motivation | Surgery | Intravenous infusion | Epirubicin | Medical research | Survival | Patients | Cisplatin | Esophagus | Interactive systems | Medical prognosis | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 03/2014, Volume 370, Issue 12, pp. 1101 - 1110
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 03/2012, Volume 30, Issue 9, pp. 980 - 988
Journal Article
by Gröbner, Susanne N and Worst, Barbara C and Weischenfeldt, Joachim and Buchhalter, Ivo and Kleinheinz, Kortine and Rudneva, Vasilisa A and Johann, Pascal D and Balasubramanian, Gnana Prakash and Segura-Wang, Maia and Brabetz, Sebastian and Bender, Sebastian and Hutter, Barbara and Sturm, Dominik and Pfaff, Elke and Hübschmann, Daniel and Zipprich, Gideon and Heinold, Michael and Eils, Jürgen and Lawerenz, Christian and Erkek, Serap and Lambo, Sander and Waszak, Sebastian and Blattmann, Claudia and Borkhardt, Arndt and Kuhlen, Michaela and Eggert, Angelika and Fulda, Simone and Gessler, Manfred and Wegert, Jenny and Kappler, Roland and Baumhoer, Daniel and Burdach, Stefan and Kirschner-Schwabe, Renate and Kontny, Udo and Kulozik, Andreas E and Lohmann, Dietmar and Hettmer, Simone and Eckert, Cornelia and Bielack, Stefan and Nathrath, Michaela and Niemeyer, Charlotte and Richter, Günther H and Schulte, Johannes and Siebert, Reiner and Westermann, Frank and Molenaar, Jan J and Vassal, Gilles and Witt, Hendrik and Zapatka, Marc and Burkhardt, Birgit and Kratz, Christian P and Witt, Olaf and Tilburg, Cornelis M. Van and Kramm, Christof M and Fleischhack, Gudrun and Dirksen, Uta and Rutkowski, Stefan and Frühwald, Michael and Hoff, Katja Von and Wolf, Stephan and Klingebiel, Thomas and Koscielniak, Ewa and Landgraf, Pablo and Koster, Jan and Resnick, Adam C and Zhang, Jinghui and Liu, Yanling and Zhou, Xin and Waanders, Angela J and Zwijnenburg, Danny A and Raman, Pichai and Brors, Benedikt and Weber, Ursula D and Northcott, Paul A and Pajtler, Kristian W and Kool, Marcel and Piro, Rosario M and Korbel, Jan O and Schlesner, Matthias and Eils, Roland and Jones, David T. W and Lichter, Peter and Chavez, Lukas and Pfister, Stefan M and ICGC PedBrain-Seq Project ICGC and ICGC MMML-Seq Project and ICGC PedBrain-Seq Project
Nature, ISSN 0028-0836, 03/2018, Volume 555, Issue 7696, pp. 321 - 327
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2014, Volume 32, Issue 5, pp. 415 - 423
Purpose Deep molecular response (MR4.5) defines a subgroup of patients with chronic myeloid leukemia (CML) who may stay in unmaintained remission after... 
MESYLATE | INTERFERON-ALPHA | THERAPY | CHRONIC-PHASE | ONCOLOGY | RECOMMENDATIONS | CLINICAL-TRIALS | 800 MG | END-POINTS | EUROPEAN-LEUKEMIANET | CHRONIC MYELOID-LEUKEMIA | Piperazines - administration & dosage | Humans | Middle Aged | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Male | Protein Kinase Inhibitors - adverse effects | Molecular Targeted Therapy | Young Adult | Benzamides - administration & dosage | Time Factors | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology | Aged, 80 and over | Adult | Female | Benzamides - adverse effects | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - enzymology | Pyrimidines - administration & dosage | Risk Factors | Proportional Hazards Models | Treatment Outcome | Imatinib Mesylate | Piperazines - adverse effects | Remission Induction | Cytarabine - administration & dosage | Disease Progression | Interferon-alpha - administration & dosage | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Fusion Proteins, bcr-abl - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Fusion Proteins, bcr-abl - antagonists & inhibitors | Pyrimidines - adverse effects | Aged | Fusion Proteins, bcr-abl - metabolism | Index Medicus
Journal Article